Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan… - medRxiv, 2022 - medrxiv.org
Background Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving
limited insights into mucosal defences that prevent viral replication and onward …
limited insights into mucosal defences that prevent viral replication and onward …
Intranasal coronavirus SARS-CoV-2 immunization with lipid adjuvants provides systemic and mucosal immune response against SARS-CoV-2 S1 spike and …
A Sengupta, M Azharuddin, ME Cardona, C Devito… - Vaccines, 2022 - mdpi.com
In this preclinical two-dose mucosal immunization study, using a combination of S1 spike
and nucleocapsid proteins with cationic (N3)/or anionic (L3) lipids were investigated using …
and nucleocapsid proteins with cationic (N3)/or anionic (L3) lipids were investigated using …
Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model
SN Langel, S Johnson, CI Martinez… - Science Translational …, 2022 - science.org
Transmission-blocking strategies that slow the spread of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and protect against coronavirus disease 2019 (COVID-19) are …
coronavirus 2 (SARS-CoV-2) and protect against coronavirus disease 2019 (COVID-19) are …
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B. 1.1. 529) and prevents transmission in hamsters
S Sharma, T Vercruysse, L Sanchez-Felipe… - Nature …, 2022 - nature.com
Current COVID-19 vaccines are based on prototypic spike sequences from ancestral 2019
SARS-CoV-2 strains. However, the ongoing pandemic is fueled by variants of concern …
SARS-CoV-2 strains. However, the ongoing pandemic is fueled by variants of concern …
[HTML][HTML] Promises and challenges of mucosal COVID-19 vaccines
APS Rathore, ALS John - Vaccine, 2023 - Elsevier
Abstract Coronavirus disease-2019 (COVID-19) is an ongoing pandemic caused by the
newly emerged virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
newly emerged virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Oral and intranasal vaccines against SARS‐CoV‐2: Current progress, prospects, advantages, and challenges
Background The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has
caused a deadly pandemic in the 21st century, resulting in many deaths, economic loss, and …
caused a deadly pandemic in the 21st century, resulting in many deaths, economic loss, and …
[HTML][HTML] Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against …
The ongoing COVID-19 pandemic caused by SARS-CoV-2 infection has threatened global
health. Since the first case of infection was reported in December 2019, SARS-CoV-2 has …
health. Since the first case of infection was reported in December 2019, SARS-CoV-2 has …
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a …
R Sunagar, SD Prasad, R Ella, KM Vadrevu - Frontiers in Immunology, 2022 - frontiersin.org
Most if not all vaccine candidates developed to combat COVID-19 due to SARS-CoV-2
infection are administered parenterally. As SARS-CoV-2 is transmitted through infectious …
infection are administered parenterally. As SARS-CoV-2 is transmitted through infectious …
Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers
T Imsuwansri, T Jongthitinon, N Pojdoung… - Scientific Reports, 2023 - nature.com
An HPMC-based nasal spray solution containing human IgG1 antibodies against SARS-
CoV-2 (nasal antibody spray or NAS) was developed to strengthen COVID-19 management …
CoV-2 (nasal antibody spray or NAS) was developed to strengthen COVID-19 management …
Intranasal immunization with liposome-displayed receptor-binding domain induces mucosal immunity and protection against SARS-CoV-2
The global pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), has led to efforts in developing effective vaccine approaches. Currently, approved …
CoV-2), has led to efforts in developing effective vaccine approaches. Currently, approved …